Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

NCT02643368 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

760

Enrollment

FED

Sponsor class

Conditions

Poliomyelitis

Interventions

BIOLOGICAL: mOPV2 at 6 and 7 weeks of age
BIOLOGICAL: mOPV2 at 6 and 8 weeks of age
BIOLOGICAL: mOPV2 at 6 and 10 weeks of age
BIOLOGICAL: IPV at 6 weeks of age

Sponsor

Centers for Disease Control and Prevention

Collaborators

[object Object]